News & Updates

Rapid point-of-care testing enables timely and targeted RTI treatment

According to the 2021 Global Burden of Disease (GBD) study, COVID-19 and lower respiratory tract infections (LRTIs) ranked as the 1st and 5th leading causes of global disease burden across all age groups and genders.

Rapid point-of-care tests (POCTs) enable timely diagnosis, particularly in vulnerable populations at higher risk of severe illness, complications, and hospitalization. 

การฉีดวัคซีนเป็นกลยุทธ์สำคัญในการป้องกันและควบคุมไข้เลือดออกในภูมิภาคเอเชียตะวันออกเฉียงใต้

เอเชียตะวันออกเฉียงใต้ (Southeast Asia; SEA) เป็นพื้นที่เสี่ยงติดเชื้อไข้เลือดออก โดยอินโดนีเซียและไทยเป็นประเทศที่พบการระบาดสูง ในงานสัมมนาระหว่างการประชุมสุดยอด APIC-ADVA ประจำภูมิภาคเอเชียแปซิฟิกครั้งที่ 2 ว่าด้วยโรคติดเชื้อและการสร้างภูมิคุ้มกัน ณ ประเทศสิงคโปร์ สนับสนุนโดยบริษัท Takeda ผู้เชี่ยวชาญได้เน้นย้ำถึงการฉีดวัคซีน ซึ่งเป็นส่วนสำคัญของกลยุทธ์สำหรับการป้องกันและควบคุมไข้เลือดออกแบบองค์รวมในภูมิภาค SEA

Vaccination crucial to integrated dengue prevention and control in SEA

Southeast Asia (SEA) is one of the hotspots for dengue infections, with Indonesia and Thailand among the highly endemic countries. At a Takeda-sponsored symposium held during the 2nd APIC-ADVA Asia Pacific Summit on Infectious Diseases and Immunization in Singapore, experts focused on vaccination as an integral component of a holistic dengue prevention and control strategy in SEA.

*The editorial below is supported by Takeda Pharmaceuticals International AG Singapore Branch and is intended solely for informational purposes. Takeda has not influenced or contributed to the editorial content. While Takeda has provided financial support for the editorial, Takeda shall not be held responsible or liable for any errors, omissions, or inaccuracies in such information.

Nirmatrelvir-ritonavir efficacy and risk factors for COVID-19 hospitalization

The post-pandemic burden of COVID-19 remains significant in adults. Four studies from IDWeek 2024 highlight the benefits of nirmatrelvir-ritonavir (NMV/r) for high-risk adults with SARS-CoV-2 immunity and link chronic conditions to COVID-19 hospitalization. Identifying high-risk patients and using NMV/r in outpatient settings can reduce severe outcomes.

Clinical considerations for patients at high risk for progression to severe COVID-19

COVID-19 has not gone away. New contagious variants continue to be a leading cause of death, with underlying conditions still influencing the risk of COVID-19 hospitalizations, said Dr Ali Hassoun, Clinical Professor of Medicine and infectious disease specialist at Crestwood Medical Center, Huntsville, Alabama, US, who spoke at a Pfizer-sponsored session during IDWeek 2024.

Nirmatrelvir-ritonavir efficacy in special populations – Insights from comparative studies

Nirmatrelvir-ritonavir has emerged as a key antiviral therapy in the fight against COVID-19, particularly for high-risk populations. Two recently published studies demonstrated the efficacy of nirmatrelvir-ritonavir in hospitalized patients with COVID-19 and in those with advanced kidney disease.

COVID-19 hospitalizations remain deadlier than flu in 2023-2024

A study compared mortality rates from COVID-19 and influenza hospitalizations during fall-winter 2023-2024.¹

Antibiotic and antiviral therapy in COVID-19 patients: Updates from ESCMID Global 2024

In COVID-19 patients, antibiotic therapy should be reserved only for suspected bacterial superinfections.

However, international data from over 1 million hospitalized COVID-19 patients across 65 countries showed that antibiotics were commonly prescribed empirically despite the low rates of reported bacterial co-infection.¹

Product Highlight - Comirnaty

Raxtozinameran - Dispersion for injection

Nirmatrelvir reduces the risk of long COVID

Post-COVID condition, also known as long COVID, is a serious public health problem affecting millions of people around the world.¹